

February 3, 2016

Whom It May Concern

Company: KYORIN Holdings, Inc.
Representative: Minoru Hogawa
Representative Director, President
(Security Code: 4569, TSE 1st Sec.)
Contact: Shuji Miyaki
Director, Corporate Communication
President Office
Telephone: (0)3-3525-4707

**Termination of License Concerning
COPD Therapeutic Drug KRP-AB1102F**

TOKYO, Japan (February 3, 2016) — Kyorin Pharmaceutical Co., Ltd. (“Kyorin”) (Head office: Chiyoda-ku, Tokyo, President: Mitsutomo Miyashita), a wholly owned subsidiary of KYORIN Holdings, Inc., announced today that a license agreement for a COPD^{*1} therapeutic drug of KRP-AB1102F with AstraZeneca UK Limited (“AstraZeneca”) was terminated.

*Note) KRP-AB1102F is a combination drug containing as active ingredients Acclidinium Bromide^{*2} and Formoterol Fumarate^{*3}, “Combination Product”.*

In February 2011, Kyorin and Almirall, S.A. (Barcelona, Spain, “Almirall”) signed a license agreement giving Kyorin the rights to develop and commercialize Acclidinium Bromide (the mono product and the Combination Product) in Japan. In November 2014, AstraZeneca acquired the rights to the respiratory franchise from Almirall. In connection with the termination of the license agreement with respect to the Combination Product, Kyorin has returned the rights to develop and commercialize the Combination Product in Japan to AstraZeneca.

Kyorin has been developing the Combination Product in Japan, and in discussions with AstraZeneca about future development, we reached the conclusion that the rights should be returned to AstraZeneca. Eklira®Genuair®, the mono product of Acclidinium Bromide launched in Japan in 2015 for the treatment of COPD, will continue to be sold by Kyorin.

There are no changes to Kyorin Holdings’ consolidated earnings forecast for the fiscal year ending March 31, 2016 as a result of this matter.

###

^{*1} COPD: Chronic Obstructive Pulmonary Disease

^{*2} Acclidinium Bromide: Long-acting muscarinic M3 antagonist

^{*3} Formoterol Fumarate: Long-acting β_2 agonist